Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 201 - 250 av 510 resultater
Tid
Selskap
Tittel
Sektor
Kategori
28 Jul 2023
13:22 CEST
SANOFI
Communiqué de presse : Mise en ligne du rapport financier semestriel 2023 de Sanofi
20103015 Pharmaceuticals
Other subject
28 Jul 2023
13:22 CEST
SANOFI
Press release: Online availability of Sanofi’s half-year financial report for 2023
20103015 Pharmaceuticals
Other subject
28 Jul 2023
07:32 CEST
SANOFI
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
20103015 Pharmaceuticals
Other subject
28 Jul 2023
07:32 CEST
SANOFI
Communiqué de presse : Sanofi va acquérir Qunol®, une marque américaine à croissance rapide, spécialiste du « vieillissement en bonne santé »
20103015 Pharmaceuticals
Other subject
28 Jul 2023
07:30 CEST
SANOFI
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
20103015 Pharmaceuticals
Other subject
28 Jul 2023
07:30 CEST
SANOFI
Communiqué de presse : Solide performance au deuxième trimestre et forte progression du portefeuille R&D, Hausse des perspectives 2023
20103015 Pharmaceuticals
Other subject
18 Jul 2023
18:29 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares – June 2023
20103015 Pharmaceuticals
Share history
18 Jul 2023
18:29 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - JUIN 2023
20103015 Pharmaceuticals
Share history
17 Jul 2023
19:00 CEST
SANOFI
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
20103015 Pharmaceuticals
Other subject
17 Jul 2023
19:00 CEST
SANOFI
Communiqué de presse : La FDA approuve BeyfortusTM (nirsevimab-alip) pour la protection des nourrissons contre les infections dues au VRS
20103015 Pharmaceuticals
Other subject
29 Jun 2023
07:30 CEST
SANOFI
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
20103015 Pharmaceuticals
Other subject
29 Jun 2023
07:30 CEST
SANOFI
Communiqué de presse : Le pipeline Vaccins de Sanofi relève la barre contre le VRS, la grippe, la méningite et les infections à pneumocoques
20103015 Pharmaceuticals
Other subject
27 Jun 2023
07:30 CEST
SANOFI
Communiqué de presse : Amlitelimab : De premières données positives de phase IIb dans le traitement de la dermatite atopique confortent son potentiel de premier et de meilleur anticorps monoclonal anti-OX40L de sa catégorie
20103015 Pharmaceuticals
Other subject
27 Jun 2023
07:30 CEST
SANOFI
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
20103015 Pharmaceuticals
Other subject
25 Jun 2023
16:30 CEST
SANOFI
Communiqué : ALTUVIIIO : des données de dernière heure présentées au Congrès de l’ISTH démontrent une protection hautement efficace contre les saignements chez les enfants atteints d’hémophilie A sévère, à raison d’une dose par semaine
20103015 Pharmaceuticals
Other subject
25 Jun 2023
16:30 CEST
SANOFI
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
20103015 Pharmaceuticals
Other subject
22 Jun 2023
07:30 CEST
SANOFI
Communiqué de presse : Mise en ligne du document «Q2 2023 Memorandum for modelling purposes»
20103015 Pharmaceuticals
Other subject
22 Jun 2023
07:30 CEST
SANOFI
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
20103015 Pharmaceuticals
Other subject
20 Jun 2023
19:43 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - May 2023
20103015 Pharmaceuticals
Share history
20 Jun 2023
19:43 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - MAI 2023
20103015 Pharmaceuticals
Share history
20 Jun 2023
07:30 CEST
SANOFI
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
20103015 Pharmaceuticals
Other subject
20 Jun 2023
07:30 CEST
SANOFI
Communiqué de presse : Sanofi remporte l’arbitrage lié à Zantac initié par Boehringer Ingelheim
20103015 Pharmaceuticals
Other subject
13 Jun 2023
14:00 CEST
SANOFI
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
20103015 Pharmaceuticals
Other subject
13 Jun 2023
14:00 CEST
SANOFI
Communiqué de presse : Sanofi mise sur l'intelligence artificielle et la science des données pour accélérer les percées scientifiques au service des patients
20103015 Pharmaceuticals
Other subject
08 Jun 2023
23:19 CEST
SANOFI
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
20103015 Pharmaceuticals
Other subject
08 Jun 2023
23:19 CEST
SANOFI
Communiqué de presse : Le Comité consultatif de la FDA recommande le nirsevimab à l’unanimité comme premier agent d’immunisation contre les infections dues au VRS pour tous les nourrissons
20103015 Pharmaceuticals
Other subject
01 Jun 2023
07:30 CEST
SANOFI
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
20103015 Pharmaceuticals
Other subject
01 Jun 2023
07:30 CEST
SANOFI
Communiqué de presse : Sanofi lance son plan mondial 2023 d’actionnariat salarié
20103015 Pharmaceuticals
Other subject
31 May 2023
07:00 CEST
SANOFI
Communiqué : Des données positives de phase II relatives au frexalimab, nouvel anticorps anti-CD40L expérimental, montrent une réduction significative de l’activité de la maladie chez des patients atteints de SEP récurrente-rémittente
20103015 Pharmaceuticals
Other subject
31 May 2023
07:00 CEST
SANOFI
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
20103015 Pharmaceuticals
Other subject
25 May 2023
18:10 CEST
SANOFI
Communiqué de presse : Assemblée Générale Annuelle du 25 mai 2023 – Frédéric Oudéa nouveau Président du Conseil d’administration
20103015 Pharmaceuticals
Other subject
25 May 2023
18:10 CEST
SANOFI
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
20103015 Pharmaceuticals
Other subject
21 May 2023
20:17 CEST
SANOFI
Communiqué de presse: Dupixent® (dupilumab) : présentation de résultats de phase III de dernière heure dans le traitement de la BPCO au Congrès de l’ATS, avec publication simultanée dans le New England Journal of Medicine
20103015 Pharmaceuticals
Other subject
21 May 2023
20:17 CEST
SANOFI
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
20103015 Pharmaceuticals
Other subject
17 May 2023
22:01 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares – April 2023
20103015 Pharmaceuticals
Share history
17 May 2023
22:01 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions – Avril 2023
20103015 Pharmaceuticals
Share history
12 May 2023
10:50 CEST
SANOFI
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
20103015 Pharmaceuticals
Other subject
12 May 2023
10:50 CEST
SANOFI
Communiqué de presse : Le nirsevimab permet de réduire de 83 % les hospitalisations de nourrissons dues au VRS dans le cadre d’un essai clinique en situation réelle
20103015 Pharmaceuticals
Other subject
04 May 2023
08:00 CEST
SANOFI
Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS
20103015 Pharmaceuticals
Share history
04 May 2023
08:00 CEST
SANOFI
Sanofi: ASSEMBLEE GENERALE MIXTE DU 25 MAI 2023 - MODALITES DE MISE A DISPOSITION OU DE CONSULTATION DES DOCUMENTS PREPARATOIRES
20103015 Pharmaceuticals
Share history
27 Apr 2023
14:40 CEST
SANOFI
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
20103015 Pharmaceuticals
Other subject
27 Apr 2023
14:40 CEST
SANOFI
Communiqué de presse: Sanofi finalise l’acquisition de Provention Bio, Inc.
20103015 Pharmaceuticals
Other subject
27 Apr 2023
07:30 CEST
SANOFI
Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC
20103015 Pharmaceuticals
Other subject
27 Apr 2023
07:30 CEST
SANOFI
Communiqué de presse : Forte croissance au premier trimestre soutenue par la Médecine de Spécialités, les Vaccins et la Santé Grand Public
20103015 Pharmaceuticals
Other subject
26 Apr 2023
08:00 CEST
SANOFI
Communiqué de presse: Sanofi annonce l’expiration de la période d’attente prévue par la loi Hart-Scott-Rodino en vue de l’acquisition de Provention Bio, Inc.
20103015 Pharmaceuticals
Other subject
26 Apr 2023
08:00 CEST
SANOFI
Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.
20103015 Pharmaceuticals
Other subject
19 Apr 2023
21:05 CEST
SANOFI
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Mars 2023
20103015 Pharmaceuticals
Share history
19 Apr 2023
21:05 CEST
SANOFI
Sanofi: Information concerning the total number of voting rights and shares - March 2023
20103015 Pharmaceuticals
Share history
11 Apr 2023
08:00 CEST
SANOFI
Communiqué de presse : Nirsevimab : Sanofi, AstraZeneca et Sobi simplifient leurs accords contractuels
20103015 Pharmaceuticals
Other subject
11 Apr 2023
08:00 CEST
SANOFI
Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
20103015 Pharmaceuticals
Other subject
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
4
5
6
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Stock options
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva